Gilead Sciences Newswire

Gilead Sciences Newswire

Comprehensive Real-Time News Feed for Gilead Sciences.

Results 1 - 20 of 1,165 in Gilead Sciences

  1. Better Buy: Biogen Inc. vs. Gilead SciencesRead the original story w/Photo

    40 min ago | Fox News

    But for investors, the future matters a whole lot more than the past. Which of these two big biotech stocks is the better pick going forward? Here's how Biogen and Gilead Sciences compare.

    Comment?

  2. Gilead Sciences, Inc. (GILD) Stake Boosted by Oak Ridge Investments LLCRead the original story w/Photo

    5 hrs ago | IntersportsWire

    Oak Ridge Investments LLC grew its stake in shares of Gilead Sciences, Inc. by 5.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 85,509 shares of the biopharmaceutical company's stock after acquiring an additional 4,284 shares during the quarter.

    Comment?

  3. John F. Milligan Sells 220,000 Shares of Gilead Sciences, Inc. (GILD) StockRead the original story w/Photo

    19 hrs ago | The Breeze

    Gilead Sciences, Inc. insider John F. Milligan sold 220,000 shares of the firm's stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $72.88, for a total transaction of $16,033,600.00.

    Comment?

  4. U.S. biotechs can't shake October blues as investors await next movesRead the original story w/Photo

    Yesterday | Globe and Mail

    ... development pipelines and upcoming clinical data catalysts. So when mature-biotech names like Biogen Inc., Gilead Sciences Inc. and Celgene Corp. trimmed guidance or posted third-quarter sales that fell short of estimates, some investors ran for the ...

    Comment?

  5. Skba Capital Management LLC Raises Holdings in Gilead Sciences, Inc.Read the original story w/Photo

    Yesterday | Daily Political

    Skba Capital Management LLC grew its stake in Gilead Sciences, Inc. by 33.7% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 142,500 shares of the biopharmaceutical company's stock after purchasing an additional 35,900 shares during the quarter.

    Comment?

  6. Financial Counselors Inc. Cuts Holdings in Gilead Sciences, Inc.Read the original story w/Photo

    Yesterday | IntersportsWire

    Financial Counselors Inc. lessened its stake in Gilead Sciences, Inc. by 5.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission . The institutional investor owned 12,080 shares of the biopharmaceutical company's stock after selling 730 shares during the period.

    Comment?

  7. Watch Out Gilead, Juno's Strategy Might Just Pay OffRead the original story w/Photo

    Thursday | Seeking Alpha

    Gilead acquired Kite in a blockbuster $11.9 B deal largely for its recently approved CD19 CAR-T product platform. Kite and Novartis have established leadership in the CD19 CAR-T space implementing fast to market "first in class" strategies.

    Comment?

  8. Integrated BioSci Research On Atara Biotherapeutics: What's Next After CAR-T?Read the original story w/Photo

    Thursday | Seeking Alpha

    ... the introduction of chemotherapy). Both patients afflicted with dreaded cancers, as well as shareholders of Gilead Sciences (NASDAQ: GILD ) and Kite Pharma (now acquired by Gilead), cheered. Interestingly, there is another firm brewing a highly ...

    Comment?

  9. The search for a cureRead the original story w/Photo

    Thursday | Aidsmap

    ... scientists at the Scripps Research Institute in Florida announced Tuesday in the journal, Cell Reports. Gilead Sciences, Inc. today announced the second round of recipients of its HIV cure grants program. This new commitment will provide $7.5 ...

    Comment?

  10. How To Make Money With Gilead?Read the original story w/Photo

    Thursday | Seeking Alpha

    Growth of the Hepatitis franchises seem to be at the end of its robust cycle, but tapping into the vast China market may spark further growth. Despite stellar developments with the historic approval of CAR-T, the share price of Gilead Sciences , a growth company , continue to head South .

    Comment?

  11. Gilead Sciences, Inc. (GILD) Stake Lessened by Hennessy Advisors Inc.Read the original story w/Photo

    Thursday | Daily Political

    Hennessy Advisors Inc. cut its holdings in shares of Gilead Sciences, Inc. by 7.3% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 29,100 shares of the biopharmaceutical company's stock after selling 2,300 shares during the period.

    Comment?

  12. Eaton Vance Management Sells 213,217 Shares of Gilead Sciences, Inc.Read the original story w/Photo

    Thursday | IntersportsWire

    Eaton Vance Management lowered its holdings in shares of Gilead Sciences, Inc. by 7.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission . The institutional investor owned 2,572,625 shares of the biopharmaceutical company's stock after selling 213,217 shares during the period.

    Comment?

  13. Gilead Sciences Inc (GILD) President and CEO John F Milligan Sold $16 million of SharesRead the original story w/Photo

    Wednesday Nov 15 | GuruFocus.com

    President and CEO of Gilead Sciences Inc John F Milligan sold 220,000 shares of GILD on 11/13/2017 at an average price of $72.88 a share. The total sale was $16 million.

    Comment?

  14. Spring Bank Pharma's inarigivir shows positive effect in mid-stage HBV studyRead the original story w/Photo

    Wednesday Nov 15 | Seeking Alpha

    Spring Bank Pharmaceuticals announces positive results from the second cohort of Part A in the Phase 2 ACHIEVE study evaluating lead candidate inarigivir as a potential backbone in a combo treatment for chronic hepatitis B virus infection. The primary endpoints were safety and the change in HBV DNA from baseline to week 12. All patients transitioned to Gilead Sciences' Viread for an additional 12 weeks.

    Comment?

  15. Spring Bank Pharmaceuticals Announces Positive Top-Line Results from...Read the original story w/Photo

    Wednesday Nov 15 | GlobeNewswire

    ... endpoints. All patients in this cohort have transitioned to tenofovir disoproxil fumarate (marketed by Gilead Sciences, Inc. as VireadA ) 300mg daily for an additional 12 weeks. "We are happy to report that inarigivir 50mg daily for 12 weeks met ...

    Comment?

  16. Gilead Sciences, Inc. (GILD) Position Lowered by CIBC World Markets Inc.Read the original story w/Photo

    Wednesday Nov 15 | IntersportsWire

    CIBC World Markets Inc. lowered its stake in Gilead Sciences, Inc. by 21.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 754,584 shares of the biopharmaceutical company's stock after selling 200,321 shares during the period.

    Comment?

  17. Mayo Investment Advisers LLC Boosts Stake in Gilead Sciences, Inc.Read the original story w/Photo

    Wednesday Nov 15 | IntersportsWire

    Mayo Investment Advisers LLC lifted its position in shares of Gilead Sciences, Inc. by 11.2% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 91,253 shares of the biopharmaceutical company's stock after buying an additional 9,180 shares during the quarter.

    Comment?

  18. Gilead Sciences, Inc. (GILD) Short Interest Down 18.9% in OctoberRead the original story w/Photo

    Wednesday Nov 15 | The Breeze

    Gilead Sciences, Inc. was the target of a significant drop in short interest during the month of October. As of October 31st, there was short interest totalling 19,599,824 shares, a drop of 18.9% from the October 13th total of 24,156,580 shares.

    Comment?

  19. Freestone Capital Holdings LLC Has $20 Million Holdings in Gilead Sciences, Inc.Read the original story w/Photo

    Tuesday Nov 14 | Daily Political

    Freestone Capital Holdings LLC raised its position in shares of Gilead Sciences, Inc. by 2.2% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 282,543 shares of the biopharmaceutical company's stock after buying an additional 6,027 shares during the quarter.

    Comment?

  20. Weekly Analysts' Ratings Changes for Juno TherapeuticsRead the original story w/Photo

    Monday Nov 13 | AmericanBankingNews.com

    According to Zacks, "Juno reported narrower-than-expected loss in third-quarter 2017 with revenue beating estimates. Though Juno remains on track with its pipeline, the recent FDA approvals for Gilead's Yescarta and Novartis' Kymriah in the CAR T space, may pose competitive threats to its candidates once approved.

    Comment?